{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:38:13Z","timestamp":1785523093886,"version":"3.56.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015998","name":"ParkinsonFonds Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015998","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00415-025-13195-w","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T09:37:54Z","timestamp":1750153074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u201cHow to save a marriage\u201d: treatment of REM sleep behavior disorder (RBD) with acetyl-leucine in a patient with Parkinson\u2019s disease"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7582-8166","authenticated-orcid":false,"given":"Wolfgang H.","family":"Oertel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8295-4884","authenticated-orcid":false,"given":"Martin T.","family":"Henrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3437-0267","authenticated-orcid":false,"given":"Filip","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-5831","authenticated-orcid":false,"given":"Annette","family":"Janzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5480-0463","authenticated-orcid":false,"given":"Fanni F.","family":"Geibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9544-2279","authenticated-orcid":false,"given":"Michael","family":"Strupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"13195_CR1","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awz030","volume":"142","author":"RB Postuma","year":"2019","unstructured":"Postuma RB, Iranzo A, Hu M et al (2019) Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 142:744\u2013759. https:\/\/doi.org\/10.1093\/brain\/awz030","journal-title":"Brain"},{"key":"13195_CR2","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/mdc3.13908","volume":"10","author":"F Sixel-D\u00f6ring","year":"2023","unstructured":"Sixel-D\u00f6ring F, Muntean M-L, Petersone D et al (2023) The Increasing prevalence of rem sleep behavior disorder with Parkinson\u2019s disease progression: a polysomnography-supported study. Mov Disord Clin Pract 10:1769\u20131776. https:\/\/doi.org\/10.1002\/mdc3.13908","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"13195_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00415-024-12730-5","volume":"272","author":"A Fanciulli","year":"2025","unstructured":"Fanciulli A, Sixel-D\u00f6ring F, Buhmann C et al (2025) Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson\u2019s disease: guideline \u201cParkinson\u2019s disease\u201d of the German Society of Neurology. J Neurol 272(1):90. https:\/\/doi.org\/10.1007\/s00415-024-12730-5","journal-title":"J Neurol"},{"issue":"7","key":"13195_CR4","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1007\/s00415-021-10625-3","volume":"268","author":"T Fields","year":"2021","unstructured":"Fields T, Schoser B, Oertel W, Strupp M (2021) Acetyl-DL-leucine improves restless legs syndrome: a case report. J Neurol 268(7):2595\u20132596. https:\/\/doi.org\/10.1007\/s00415-021-10625-3","journal-title":"J Neurol"},{"key":"13195_CR5","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.1038\/s41467-024-51502-7","volume":"15","author":"WH Oertel","year":"2024","unstructured":"Oertel WH, Janzen A, Henrich MT et al (2024) Acetyl-DL-leucine in two individuals with REM sleep behavior disorder improves symptoms, reverses loss of striatal dopamine-transporter binding and stabilizes pathological metabolic brain pattern-case reports. Nat Commun 15:7619. https:\/\/doi.org\/10.1038\/s41467-024-51502-7","journal-title":"Nat Commun"},{"key":"13195_CR6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1378\/chest.14-0970","volume":"146","author":"MJ Sateia","year":"2014","unstructured":"Sateia MJ (2014) International classification of sleep disorders-third edition: highlights and modifications. Chest 146:1387\u20131394. https:\/\/doi.org\/10.1378\/chest.14-0970","journal-title":"Chest"},{"key":"13195_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12759","volume":"71","author":"D Kunz","year":"2021","unstructured":"Kunz D, Stotz S, Bes F (2021) Treatment of isolated REM sleep behavior disorder using melatonin as a chronobiotic. J Pineal Res 71:e12759. https:\/\/doi.org\/10.1111\/jpi.12759","journal-title":"J Pineal Res"},{"key":"13195_CR8","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2147\/NSS.S372823","volume":"14","author":"J-S Jun","year":"2022","unstructured":"Jun J-S, Sunwoo J-S, Byun J-I et al (2022) Emotional and environmental factors aggravating dream enactment behaviors in patients with isolated REM sleep behavior disorder. Nat Sci Sleep 14:1713\u20131720. https:\/\/doi.org\/10.2147\/NSS.S372823","journal-title":"Nat Sci Sleep"},{"key":"13195_CR9","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1007\/s00415-013-7016-x","volume":"260","author":"M Strupp","year":"2013","unstructured":"Strupp M, Teufel J, Habs M et al (2013) Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J Neurol 260:2556\u20132561. https:\/\/doi.org\/10.1007\/s00415-013-7016-x","journal-title":"J Neurol"},{"key":"13195_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041050","author":"E Kaya","year":"2020","unstructured":"Kaya E, Smith DA, Smith C et al (2020) beneficial effects of acetyl-DL-leucine (ADLL) in a mouse model of Sandhoff disease. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9041050","journal-title":"J Clin Med"},{"key":"13195_CR11","doi-asserted-by":"publisher","first-page":"e1072","DOI":"10.1212\/WNL.0000000000201660","volume":"100","author":"K Martakis","year":"2023","unstructured":"Martakis K, Claassen J, Gascon-Bayari J et al (2023) Efficacy and safety of N-Acetyl-l-leucine in children and adults with GM2 gangliosidoses. Neurology 100:e1072\u2013e1083. https:\/\/doi.org\/10.1212\/WNL.0000000000201660","journal-title":"Neurology"},{"key":"13195_CR12","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1212\/WNL.0000000000002041","volume":"85","author":"T Bremova","year":"2015","unstructured":"Bremova T, Malinov\u00e1 V, Amraoui Y et al (2015) Acetyl-dl-leucine in Niemann-Pick type C: a case series. Neurology 85:1368\u20131375. https:\/\/doi.org\/10.1212\/WNL.0000000000002041","journal-title":"Neurology"},{"key":"13195_CR13","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00415-021-10717-0","volume":"269","author":"T Bremova-Ertl","year":"2022","unstructured":"Bremova-Ertl T, Claassen J, Foltan T et al (2022) Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C. J Neurol 269:1651\u20131662. https:\/\/doi.org\/10.1007\/s00415-021-10717-0","journal-title":"J Neurol"},{"key":"13195_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2310151","volume":"390","author":"T Bremova-Ertl","year":"2024","unstructured":"Bremova-Ertl T, Ramaswami U, Brands M et al (2024) Trial of N-Acetyl-l-Leucine in Niemann-Pick disease type C. N Engl J Med 390:421\u2013431. https:\/\/doi.org\/10.1056\/NEJMoa2310151","journal-title":"N Engl J Med"},{"key":"13195_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1046\/j.0953-816x.2000.01447.x","volume":"13","author":"N Vibert","year":"2001","unstructured":"Vibert N, Vidal PP (2001) In vitro effects of acetyl-DL-leucine (tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig. Eur J Neurosci 13:735\u2013748. https:\/\/doi.org\/10.1046\/j.0953-816x.2000.01447.x","journal-title":"Eur J Neurosci"},{"key":"13195_CR16","doi-asserted-by":"publisher","first-page":"fcaa148","DOI":"10.1093\/braincomms\/fcaa148","volume":"3","author":"E Kaya","year":"2021","unstructured":"Kaya E, Smith DA, Smith C et al (2021) Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Commun 3:fcaa148. https:\/\/doi.org\/10.1093\/braincomms\/fcaa148","journal-title":"Brain Commun"},{"key":"13195_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fneur.2015.00123","volume":"6","author":"JJ Fraigne","year":"2015","unstructured":"Fraigne JJ, Torontali ZA, Snow MB et al (2015) REM sleep at its core-circuits, neurotransmitters, and pathophysiology. Front Neurol 6:123. https:\/\/doi.org\/10.3389\/fneur.2015.00123","journal-title":"Front Neurol"},{"key":"13195_CR18","doi-asserted-by":"publisher","first-page":"15812","DOI":"10.1038\/s41598-021-95255-5","volume":"11","author":"GC Churchill","year":"2021","unstructured":"Churchill GC, Strupp M, Factor C et al (2021) Acetylation turns leucine into a drug by membrane transporter switching. Sci Rep 11:15812. https:\/\/doi.org\/10.1038\/s41598-021-95255-5","journal-title":"Sci Rep"},{"key":"13195_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229585","volume":"15","author":"GC Churchill","year":"2020","unstructured":"Churchill GC, Strupp M, Galione A et al (2020) Unexpected differences in the pharmacokinetics of N-acetyl-DL-leucine enantiomers after oral dosing and their clinical relevance. PLoS ONE 15:e0229585. https:\/\/doi.org\/10.1371\/journal.pone.0229585","journal-title":"PLoS ONE"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13195-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13195-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13195-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T06:26:24Z","timestamp":1752301584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13195-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["13195"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13195-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This single case observational study has been conducted with the drug TanganilR. This drug contains the racemate acetyl-DL-leucine, i.e., to equal parts the bio-inactive substance acetyl-D-leucine and the bioactive enantiomer acetyl-L-leucine. This drug is produced by the company Pierre Fabre, Medicaments, France and approved for the indication vertigo in France. The company Pierre Fabre was not aware of our observational study as none of the authors had any contact during and after the conduct of the study with the company. Wolfgang Oertel (WO) and Michael Strupp (MS) are members of the scientific advisory board of the company IntraBio. WO holds stock options of the company IntraBio, whereas MS is an investor and shareholder of the company Intrabio. In addition, we declare that neither the company Pierre Fabre nor the company IntraBio have supported the conduct of the case report submitted with this article by any means. Wolfgang H. Oertel also acts as a consultant for the company MODAG. He holds stock options with MODAG unrelated to this work. The institution of W.H.O., not W.H.O personally received\/s scientific grants from the ParkinsonFonds Deutschland related to the manuscript and from the German Research Foundation, Stichting Parkinson-Fonds, The Netherlands and the Michael J Fox Foundation, USA, all unrelated to the manuscript. Martin T. Henrich has no conflict of interest to declare. Filip Bergquist has no conflict of interest to declare. Annette Janzen has no conflict of interest to declare. Fanni F. Geibl has no conflict of interest to declare. Michael Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He acts as a consultant for Abbott, AurisMedical, Bulbitec, Heel, Sensorion and Vertify. The institution of M.S., not M.S. personally received\/s support for clinical studies from Decibel, U.S.A., Cure within Reach, U.S.A. and Heel, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Supplementary Material for ethical considerations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}],"article-number":"466"}}